ResearcherCenter of Medical Innovation and Translational Research, The University of OsakaActive in the last 2 years
Yu Takeda
Matched on ORCID iD 0000-0001-7210-5096. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: 3 papers
Papers 6
- Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patie… First author DOI 10.1016/j.ejso.2024.108650↗
- High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Co-author DOI 10.1111/cas.16152↗
- MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0310328↗
- Pancreatic fibrosis by extracellular volume fraction using Contrast-enhanced computed tomography and relationship with pancreatic cancer. Co-author DOI 10.1016/j.ejrad.2022.110522↗
- Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.104659↗
- Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. Co-author DOI 10.3390/cells9071645↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hidetoshi Eguchi · 6 shared papers, 2020–2024 · strength 0.88
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. DOI 10.1371/journal.pone.0310328↗
- Paper High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. DOI 10.1111/cas.16152↗
- Daisaku Yamada · 6 shared papers, 2020–2024 · strength 0.88
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. DOI 10.1371/journal.pone.0310328↗
- Paper High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. DOI 10.1111/cas.16152↗
- Yuichiro Doki · 5 shared papers, 2020–2024 · strength 0.75
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. DOI 10.1371/journal.pone.0310328↗
- Paper High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. DOI 10.1111/cas.16152↗
- Kazuki Sasaki · 4 shared papers, 2022–2024 · strength 0.66
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. DOI 10.1371/journal.pone.0310328↗
- Paper High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. DOI 10.1111/cas.16152↗
- Yoshito Tomimaru · 3 shared papers, 2022–2024 · strength 0.50
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. DOI 10.1371/journal.pone.0310328↗
- Paper Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. DOI 10.1016/j.isci.2022.104659↗
- Hidenori Takahashi · 3 shared papers, 2022–2024 · strength 0.47
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. DOI 10.1111/cas.16152↗
- Paper Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. DOI 10.1016/j.isci.2022.104659↗
- Tadafumi Asaoka · 2 shared papers, 2024 · strength 0.39
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. DOI 10.1371/journal.pone.0310328↗
- Yoshifumi Iwagami · 2 shared papers, 2024 · strength 0.39
- Paper Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plu… DOI 10.1016/j.ejso.2024.108650↗
- Paper MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. DOI 10.1371/journal.pone.0310328↗
- Hideshi Ishii · 3 shared papers, 2020–2024 · strength 0.36
- Paper High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. DOI 10.1111/cas.16152↗
- Paper Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. DOI 10.1016/j.isci.2022.104659↗
- Paper Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. DOI 10.3390/cells9071645↗
- Kazuhiko Ogawa · 2 shared papers, 2022–2024 · strength 0.27
- Shotaro Tatekawa · 2 shared papers, 2022–2024 · strength 0.27
- Yoshiko Tsuji · 1 shared paper, 2024 · strength 0.16
- Tomoaki Hara · 1 shared paper, 2024 · strength 0.16
- Hiromichi Sato · 1 shared paper, 2024 · strength 0.16
- Sikun Meng · 1 shared paper, 2024 · strength 0.16
- Noriyuki Tomiyama · 1 shared paper, 2022 · strength 0.13
- Yasunari Fukuda · 1 shared paper, 2022 · strength 0.13
- Hideyuki Fukui · 1 shared paper, 2022 · strength 0.13
- Takahiro Tsuboyama · 1 shared paper, 2022 · strength 0.13
- Ryota Chijimatsu · 1 shared paper, 2022 · strength 0.11
- Ayumu Asai · 1 shared paper, 2020 · strength 0.09
- Hirofumi Akita · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.